NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR...
Researchers Publish Manuscript on the Prevention Response to Tularemia Outbreaks
FDA approved LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND...
Appili Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate
Appili Reports Financial Results for Second Quarter of Fiscal Year 2024
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
Appili Therapeutics Presents at the 10th International Tularemia Conference
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update